{"version":"1.0","provider_name":"Merck.com","provider_url":"https:\/\/vip2-msd.com\/merckcom-migrated","author_name":"Merck.com","author_url":"https:\/\/vip2-msd.com\/merckcom-migrated","title":"Merck Statement Regarding CUBICIN Patent Litigation - Merck.com","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"0cEJ2eD7vF\"><a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-regarding-cubicin-patent-litigation\/\">Merck Statement Regarding CUBICIN Patent Litigation<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-regarding-cubicin-patent-litigation\/embed\/#?secret=0cEJ2eD7vF\" width=\"600\" height=\"338\" title=\"&#8220;Merck Statement Regarding CUBICIN Patent Litigation&#8221; &#8212; Merck.com\" data-secret=\"0cEJ2eD7vF\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/vip2-msd.com\/merckcom-migrated\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Company Reaffirms Transaction To Proceed as Planned; Expected to Close in First Quarter of 2015 Merck, known as MSD outside the United States and Canada, issued the following statement regarding the decision of the U.S. District Court for the District of Delaware. The decision, which upheld the patent for CUBICIN that expires on June 15, 2016 and invalidated four others, is subject to appeal. The company continues to believe the acquisition of Cubist will create strong fundamental value for Merck\u2019s shareholders. The combined strength of both companies will provide both incremental and long-term value, and Merck expects the transaction to add more than $1 billion of revenue to its 2015 base, with strong growth potential thereafter. The court\u2019s decision does not change Merck\u2019s expectation that the transaction will be neutral to modestly accretive to 2015 non-GAAP EPS. The company also continues to expect that the transaction will contribute mid-single digit accretion on a","thumbnail_url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141209005647r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en"}